Immunocore (IMCR) – Investment Analysts’ Recent Ratings Updates

Several brokerages have updated their recommendations and price targets on shares of Immunocore (NASDAQ: IMCR) in the last few weeks:

• 8/3/2026 – Immunocore had its price target raised by Mizuho from $34.00 to $35.00. They now have a “neutral” rating on the stock.
• 7/28/2026 – Immunocore was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/20/2026 – Immunocore was upgraded by Wall Street Zen from “hold” to “buy”.
• 7/17/2026 – Immunocore had its “sell (e+)” rating reaffirmed by Weiss Ratings.
• 7/13/2026 – Immunocore had its “overweight” rating reaffirmed by Cantor Fitzgerald.
• 7/12/2026 – Immunocore was downgraded by Wall Street Zen from “buy” to “hold”.
• 7/7/2026 – Immunocore was downgraded by Zacks Research from “strong-buy” to “hold”.

Immunocore plc is a clinical‐stage biotechnology company focused on the development of novel immunotherapies that harness the body’s own T‐cell response to treat cancer and infectious diseases. The company’s proprietary ImmTAC (immune mobilising monoclonal T‐cell receptors against cancer) platform utilizes engineered, soluble T‐cell receptor (TCR) molecules designed to recognise intracellular peptide–HLA complexes. By redirecting and activating T cells against disease‐associated targets, Immunocore aims to address malignancies and persistent viral infections with high unmet medical need.

The company’s most advanced candidate, tebentafusp, is a bispecific ImmTAC molecule that targets gp100, a melanoma‐associated antigen, and has received regulatory approval for the treatment of metastatic uveal melanoma.